Vittorio Fusco

Dr. Vittorio Fusco

Medical Oncology Unit, Azienda Ospedaliera di Alessandria, 15121 Alessandria, Italy

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Giuseppina CampisiGiuseppina Campisi
Giuseppina Campisi
Rodolfo MauceriRodolfo Mauceri
Rodolfo Mauceri
FBFrancesco Bertoldo
Francesco Bertoldo
Giordana BettiniGiordana Bettini
Giordana Bettini
MBMatteo Biasotto
Matteo Biasotto
Alberto BedogniAlberto Bedogni
Alberto Bedogni
The Medication-Related Osteonecrosis of Jaws (MRONJ) diagnosis process and its prevention play a role of great and rising importance, not only on the Quality of Life (QoL) of patients, but also on the decision-making process by the majority of dentists and oral surgeons involved in MRONJ prevention (primary and secondary). The present paper reports the update of the conclusions from the Consensus Conference—held at the Symposium of the Italian Society of Oral Pathology and Medicine (SIPMO) (20 October 2018, Ancona, Italy)—after the newest recommendations (2020) on MRONJ were published by two scientific societies (Italian Societies of Maxillofacial Surgery and Oral Pathology and Medicine, SICMF and SIPMO), written on the inputs of the experts of the Italian Allied Committee on ONJ (IAC-ONJ). The conference focused on the topic of MRONJ, and in particular on the common practices at risk of inappropriateness in MRONJ diagnosis and therapy, as well as on MRONJ prevention and the dental management of patients at risk of MRONJ. It is a matter of cancer and osteometabolic patients that are at risk since being exposed to several drugs with antiresorptive (i.e., bisphosphonates and denosumab) or, more recently, antiangiogenic activities. At the same time, the Conference traced for dentists and oral surgeons some easy applicable indications and procedures to reduce MRONJ onset risk and to diagnose it early. Continuous updating on these issues, so important for the patient community, is recommended.

1 September 2014 in British Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Open access
Alberto BedogniAlberto Bedogni
Alberto Bedogni
SFStefano Fedele
Stefano Fedele
GBGiorgio Bedogni
Giorgio Bedogni
MSMatteo Scoletta
Matteo Scoletta
GFGianfranco Favia
Gianfranco Favia
Giuseppina CampisiGiuseppina Campisi
Giuseppina Campisi
Management of osteonecrosis of the jaw associated with antiresorptive agents is challenging, and outcomes are unpredictable. The severity of disease is the main guide to management, and can help to predict prognosis. Most available staging systems for osteonecrosis, including the widely-used American Association of Oral and Maxillofacial Surgeons (AAOMS) system, classify severity on the basis of clinical and radiographic findings. However, clinical inspection and radiography are limited in their ability to identify the extent of necrotic bone disease compared with computed tomography (CT). We have organised a large multicentre retrospective study (known as MISSION) to investigate the agreement between the AAOMS staging system and the extent of osteonecrosis of the jaw (focal compared with diffuse involvement of bone) as detected on CT. We studied 799 patients with detailed clinical phenotyping who had CT images taken. Features of diffuse bone disease were identified on CT within all AAOMS stages (20%, 8%, 48%, and 24% of patients in stages 0, 1, 2, and 3, respectively). Of the patients classified as stage 0, 110/192 (57%) had diffuse disease on CT, and about 1 in 3 with CT evidence of diffuse bone disease was misclassified by the AAOMS system as having stages 0 and 1 osteonecrosis. In addition, more than a third of patients with AAOMS stage 2 (142/405, 35%) had focal bone disease on CT. We conclude that the AAOMS staging system does not correctly identify the extent of bony disease in patients with osteonecrosis of the jaw.

olga di fedeolga di fede
olga di fede
FCFederica Canepa
Federica Canepa
Vera PanzarellaVera Panzarella
Vera Panzarella
Rodolfo MauceriRodolfo Mauceri
Rodolfo Mauceri
CGCarmine Del Gaizo
Carmine Del Gaizo
Antonio GalvanoAntonio Galvano
Antonio Galvano
Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents, and it is also a potentially painful and debilitating condition. To date, no specific studies have prospectively evaluated the efficacy of its treatment and no robust standard of care has been established. Therefore, a systematic review (2007–2020) with a pooled analysis was performed in order to compare MRONJ surgical techniques (conservative or aggressive) versus combined surgical procedures (surgery plus a non-invasive procedure), where 1137 patients were included in the pooled analysis. A statistically significant difference in the 6-month improvement rate, comparing combined conservative surgery versus only aggressive (91% versus 72%, p = 0.05), was observed. No significant difference regarding any group with respect to the 6-month total resolution rate (82% versus 72%) was demonstrated. Of note, conservative surgery combined with various, adjuvant, non-invasive procedures (ozone, LLLT or blood component + Nd:YAG) was found to achieve partial or full healing in all stages, with improved results and the amelioration of many variables. In conclusion, specific adjuvant treatments associated with minimally conservative surgery can be considered effective and safe in the treatment of MRONJ, although well-controlled studies are a requisite in arriving at definitive statements

1 August 2015 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
Vittorio FuscoVittorio Fusco
Vittorio Fusco
CPCamillo Porta
Camillo Porta
GSGiorgia Saia
Giorgia Saia
CPChiara Paglino
Chiara Paglino
Giordana BettiniGiordana Bettini
Giordana Bettini
Alberto BedogniAlberto Bedogni
Alberto Bedogni

Verified
Journal Article
Open access
PDF file
IRIlaria Roato
Ilaria Roato
Rodolfo MauceriRodolfo Mauceri
Rodolfo Mauceri
VNVincenzo Notaro
Vincenzo Notaro
Tullio GenovaTullio Genova
Tullio Genova
Vittorio FuscoVittorio Fusco
Vittorio Fusco
Federico MussanoFederico Mussano
Federico Mussano
The pathogenesis of medication-related osteonecrosis of the jaw (MRONJ) is multifactorial and there is a substantial consensus on the role of antiresorptive drugs (ARDs), including bisphosphonates (BPs) and denosumab (Dmab), as one of the main determinants. The time exposure, cumulative dose and administration intensity of these drugs are critical parameters to be considered in the treatment of patients, as cancer patients show the highest incidence of MRONJ. BPs and Dmab have distinct mechanisms of action on bone, but they also exert different effects on immune subsets which interact with bone cells, thus contributing to the onset of MRONJ. Here, we summarized the main effects of ARDs on the different immune cell subsets, which consequently affect bone cells, particularly osteoclasts and osteoblasts. Data from animal models and MRONJ patients showed a deep interference of ARDs in modulating immune cells, even though a large part of the literature concerns the effects of BPs and there is a lack of data on Dmab, demonstrating the need to further studies.

16 March 2022 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
Rodolfo MauceriRodolfo Mauceri
Rodolfo Mauceri
RCRita Coniglio
Rita Coniglio
AAAntonia Abbinante
Antonia Abbinante
PCPaola Carcieri
Paola Carcieri
DTDomenico Tomassi
Domenico Tomassi
Giuseppina CampisiGiuseppina Campisi
Giuseppina Campisi
Purpose: The prevention and early diagnosis of medication-related osteonecrosis of the jaw (MRONJ) is fundamental to reducing the incidence and progression of MRONJ. Many in the field believe that dental hygienists should play an integral role in primary and secondary MRONJ prevention. However, to date, very few publications in the literature have proposed standardised MRONJ protocols, which are dedicated to dental hygienists. The aim of this study was to provide guidance to the health care providers managing MRONJ. Methods: The expert opinion in this study was developed by dental hygienists from the main Italian technical-scientific associations (Italian Dental Hygienists Association, AIDI and National Union of Dental Hygienists, UNID) and authors of the latest Italian recommendations regarding MRONJ from the field of dentistry and maxillofacial surgery. Results: The oral care protocol outlined in this position paper is focused on the role of dental hygienist in patients at risk or affected by MRONJ, and it regards 3 main issues: primary prevention, secondary prevention and supporting the treatment of MRONJ. Each issue contains easy-to-apply indications and procedures, as described by the authors, regarding the role of the dental hygienist. Conclusion: Referring to the main issues under consideration (primary prevention, secondary prevention and the treatment of MRONJ), a clinical examination of periodontal tissue is critical in preventing MRONJ. It is the opinion of the authors of this study that the application of a periodontal screening score is fundamental in defining personalised strategies for patients at risk of MRONJ. By means of these basic procedures, a protocol for assisting the health care provider and the presentation of a practical approach for patients at risk or affected by MRONJ are described in this study.